top border
top border
Featured

Dr Shannon Westin On PARP Inhibition for Ovarian Cancer
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

View more >>>

Sponsored

AstraZeneca: Pioneers in Ovarian Cancer
Over two years ago, women diagnosed with germline BRCA-mutated advanced ovarian cancer had limited treatment options, including chemotherapy or investigational treatments through clinical trials. Now, that has changed. View more >>>

Featured Video

Hepatocellular Carcinoma (HCC):
Can We Improve Patient Survival?

Hepatocellular Carcinoma (HCC): Can We Improve Patient Survival?
Richard Finn, MD, Laura M. Kulik, MD, and Matthew S. Johnson, MD, FSIR, discuss the evolving systemic treatment paradigm for patients with advanced hepatocellular carcinoma. View now

Gina Columbus

Gina Columbus reports on the latest news in oncology in this week's edition of OncLive News Network.

Publication Bottom Border
Border Publication
x